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Heparin and heparin fragments in the molecular 
mass range  1,700-20,000  Da  were  examined  for  their 
ability  to  accelerate  the  antithrombin I11 (AT 111)-de- 
pendent  inhibition of human  factor Xa and  the  pro- 
thrombin converting complex (prothrombinase) dur- 
ing human  prothrombin  activation.  The  prothrombin- 
ase reaction was modeled by a 3-parameter 2- 
exponential  equation  to  determine  the  initial rate of 
prothrombin  activation  and  the  pseudo-first  order rate 
constants of inhibition of prothrombinase  and in  situ 
generated  thrombin  activity.  The  catalytic specific  ac- 
tivities of the  heparins  increased  with  increasing mo- 
lecular  size  for  both  the  inhibition of prothrombinase 
and  factor Xa. A 10-fold  increase  over  the  entire M, 
range was found. In contrast to results obtained by 
others (Ellis, V., Scully, M. F., and Kakkar, V. V. 
(1986) Biochem. J. 233, 161-165; Barrowcliffe, T. 
W., Havercroft, S. J., Kemball-Cook, G., and  Lindahl, 
U. (1987) Biochem. J. 243, 31-37), all  the  heparins 
showed a 5-fold higher  rate of inhibition of factor Xa 
when  compared  with  the  inhibition f prothrombinase, 
indicating  that  the  factor Va-mediated protection of 
factor Xa from  inhibition  by AT III/heparin is inde- 
pendent of the molecular  size of the  heparin.  Our  orig- 
inal approach has also revealed a hitherto unrecog- 
nized  phenomenon,  namely, in  addition  to the acceler- 
ating  effect of the  heparins on the  rate of formation of 
the  inactive AT 111-factor Xa complex, heparins  with 
M, > 4,500  reduce  the initial rate of thrombin  gener- 
ation in the presence of AT I11 in a concentration- 
dependent  way. We hypothesize that  the formation of 
the dissociable ternary AT 111-heparin-factor Xa com- 
plex results in a (partial) loss of factor Xa activity 
towards  its  natural  substrate  prothrombin. 
One of the essential zymogen activation reactions of the 
blood coagulation cascade leading to  the formation of insolu- 
ble fibrin strands is the activation of prothrombin by pro- 
thrombinase, a Ca2+-dependent complex composed of the 
serine protease factor Xa,  the non-enzymatic cofactor factor 
Va, and negatively charged phospholipids (Ref. 1 and refer- 
ences therein). 
A major inhibitor of coagulation is antithrombin I11 (AT 
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marked “advertisement” in accordance with 18 U.S.C. Section 1734 
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istry, University of Limburg, P. 0. Box 616, 6200 MD Maastricht, 
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III),’ a plasma protein which forms equimolar complexes with 
serine proteases of the coagulation system. In  the presence of 
heparin the rates of inactivation of the proteases are enhanced 
(2). Previous studies have monitored the rate constant of 
inactivation of free factor Xa as  a function of the molecular 
weight of heparin (3, 4). It was shown that although the 
binding of factor Xa and AT I11 to  the same heparin molecule 
is not  a prerequisite for catalysis of the inactivation of this 
protease, as it is for the inactivation of thrombin,  the  rate of 
factor Xa inactivation does increase with increasing heparin 
molecular weight. 
Studies in purified systems have demonstrated that  the AT 
111-dependent rate of inactivation of factor Xa is reduced 
when factor Xa is bound to a phospholipid surface in the 
presence of factor V ( 5 )  or factor Va (6, 7) or when bound to 
activated platelets (8), i.e. factor Xa is protected from inacti- 
vation by AT 111. It was also shown that factor Xa,  as part of 
the prothrombinase complex, is protected from heparin-cat- 
alyzed inhibition by AT I11 (5, 7, 8). However, the effect of 
the molecular  size of heparin on the  rate constant of inacti- 
vation of prothrombinase, and consequently on the  extent of 
protection, has  not been extensively studied. Moreover, the 
data available are conflicting. In one study it was observed 
that when factor Xa is bound to activated platelets the pro- 
tective effect diminishes with decreasing heparin molecular 
weight (8), whereas in a second study, where factor Xa was 
bound to a phospholipid surface in the presence of factor V, 
it appeared that the protective effect became more pro- 
nounced with decreasing molecular weight ( 5 ) .  The latter 
observation led to  the postulation that  the lack of correlation 
between in uitro anti-factor Xa activity and  antithrombotic 
action of  low molecular weight heparin is caused by different 
inhibitory actions on free factor Xa and on factor Xa in its 
more  physiological form, i.e. part of the prothrombinase com- 
plex ( 5 ) .  
Because the heparin-catalyzed AT 111-dependent inactiva- 
tion of factor Xa, as part of the prothrombinase, is not 
thoroughly investigated, we further explored this inhibition 
of factor Xa. In an  attempt  to imitate physiological conditions 
of factor  Xa inactivation as close as possible, we studied the 
effect of A T  I11 and heparin on factor Xa during human 
prothrombin activation in the presence of excess factor Va 
and phospholipid. We  developed a mathematical model  which 
adequately describes the thrombin generation curves as a 
time-dependent function of the initial  rate of prothrombin 
activation and  the pseudo-first order rate  constants of in situ 
inhibition of factor Xa and  thrombin. 
The abbreviations used are: AT 111, antithrombin 111; S2238, D- 
phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride; 
S2337, benzoyl-~-isoleucyl-~-glutamyl-(y-piperidyl~-~-glycyl-~-arg~- 
nine-p-nitroanilide hydrochloride; HSA, human serum albumin; STI, 
soybean trypsin inhibitor; ISH, the Fourth International Standard 
for Heparin. 
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Inhibition of Prothrombinase Activity 10003 
This approach made it possible to quantitatively assess the 
effect of heparin and heparin  fragments on the inhibition of 
prothrombinase  during  prothrombin  activation. We observed 
a  correlation between molecular size of the heparin  fractions 
and  their catalytic specific activity/mol of AT 111-binding site. 
Furthermore, we present evidence that, in addition to the 
progressive heparin-catalyzed reaction, heparins of higher 
molecular weight (M, >SOOO), but  not of low molecular weight 
cause an immediate, AT 111-dependent inhibition of pro- 
thrombinase activity. 
EXPERIMENTAL PROCEDURES 
Materials-The Fourth International Standard for Heparin (ISH) 
was obtained from the National Institute for Biological Standards 
and Control, London, United Kingdom. The preparation has an 
activity of 1780 international  units of heparin/ampule of 9.2 mg (9). 
The high molecular weight heparin (heparin fraction D, batch  RB 
20 292), the low molecular weight heparin (CY216, batch: P46 XH), 
and  the synthetic pentasaccharide heparin (IC83.1423, batch ILS 6 
388 B) were kindly donated by Choay Institut,  Paris, France. Heparin 
fraction D was isolated from a commercial pig mucosal heparin by 
ion-exchange chromatography on DEAE-Sephacel and has  a mean 
molecular weight of  20,300. The isolation as well as  the physicochem- 
ical and biological properties of heparin fraction D are described in 
detail elsewhere (10). The CY216  was prepared by ethanol  extraction 
of a commercial pig mucosal heparin (ll), the mean molecular weight 
is 4,500 (80% of the material has  a molecular weight between 2,400 
and 7,200 50% of the material is composed of dodeca-, tetradeca-, 
and hexadecasaccharides) and the specific activities are 200 anti- 
factor Xa units/mg and 10-20 anti-thrombin units/mg dry weight 
(data provided by Choay Institut).  The pentasaccharide was synthe- 
sized as previously described, has  a molecular weight of 1,714, and  an 
activity of  4,000 anti-factor Xa units/mg dry weight (12). 
High affinity heparin oligosaccharides were prepared by AT III- 
affinity chromatography and gel chromatography of nitrous acid- 
depolymerized heparin (13), and were a gift of Dr. Lindahl, Swedish 
University of Agricultural Sciences, Uppsala, Sweden. The oligosac- 
charides used in this study were an octasaccharide fragment, a 10-14 
and a 18-24 saccharide fragment. The (mean) molecular weights of 
these oligosaccharides were calculated with M, = 300 for each sac- 
charide unit (13). 
The molar concentrations of all heparin preparations used in this 
study were determined by stoichiometric titration of AT 111 (1 p ~ )  
in 50 mM Tris-HCl  (pH 7.5) and 100 mM NaC1, as monitored by the 
intrinsic protein fluorescence enhancement a t  X,, = 345 and 285 
nm (14). The chromogenic substrates S2238 and S2337 were pur- 
chased from KabiVitrum AB, Stockholm, Sweden. The specific 
thrombin  inhibitor hirudin was obtained from Sigma. All other pro- 
tein  preparations and  the mixed phospholipid vesicles  were prepared 
as previously described (15, 16). 
Determination of Pseudo-first Order Rate Constants of Inhibition 
of Factor Xa-The inhibition of factor Xa by AT I11 and heparin was 
performed under pseudo-first order conditions. Factor  Xa was added 
to a mixture of AT 111, prothrombin, CaC12, phospholipid vesicles 
composed of 20  mol % phosphatidylserine and 80 mol % phosphati- 
dylcholine, and heparin in 50 mM Tris-HC1 (pH 7.9), 175 mM NaCl, 
and 0.5 mg of HSA/ml at 37  "C. The final concentrations were 5.0 
nM factor Xa, 0.40 p M  AT 111, 1.5 p M  prothrombin, 3.0 mM CaC12, 
and 50 p~ phospholipid. The final heparin concentrations varied 
between 1.0 and 20 nM. At timed intervals  after the addition of factor 
Xa, 40-rl samples were transferred to cuvettes containing 0.46  ml  of 
50 mM Tris-HC1 (pH 7.9), 175 mM NaCl, 20 mM EDTA, 0.22 mM 
S2337,0.20 pM hirudin, and 0.5 mg of HSA/ml at 37 "C. Hirudin was 
present to prevent interference of thrombin formed in the first reagent 
mixture with the amidolytic factor Xa assay. After sampling into the 
substrate solution, the rate of AT  111-dependent inactivation of factor 
Xa was sufficiently slow not to result in any measurable loss of 
enzymatic activity during the recording of the absorbance. 
The rate of increase of absorbance at 405  nm  was measured on a 
dual wavelength spectrophotometer (reference wavelength: 500 nm) 
and the residual factor Xa concentrations were calculated from a 
standard curve constructed under the same conditions. Residual 
factor Xa was exponentially plotted  against reaction time and the 
pseudo-first order rate constants of inactivation of factor  Xa were 
calculated as  the slopes of these plots. 
Prothrombin Activation in the Presence of AT IZZ and Heparin- 
Human prothrombin was activated by simultaneously adding pro- 
thrombin and AT I11 to a mixture of factor Xa, factor Va, CaC12, 
phospholipid vesicles  composed of 20 mol % phosphatidylserine and 
80 mol % phosphatidylcholine, and heparin in 50 mM Tris-HC1 (pH 
7.9), 175 mM NaCl, and 0.5  mg  of HSA/ml at 37 "C. The final 
concentrations were 2.0 PM factor Xa, 0.60 nM factor Va, 3.0 mM 
CaC12, 50 p~ phospholipid, 1.5 p~ prothrombin, and 0.40 p M  AT 111. 
The final heparin concentrations varied between  1.3 and 50 nM. After 
5 min of prothrombin activation, a small aliquot (3 pl) of soybean 
trypsin inhibitor (STI) was added to a final concentration of 1.0 mg/ 
ml. After the addition of ST1 no further prothrombin activation 
occurred, which  made it possible to determine the rate of inactivation 
of thrombin activity (15). At timed intervals  during the experiment 
20-pl samples were transferred to cuvettes containing 0.48  ml  of  50 
mM Tris-HC1 (pH 7.9), 175 mM NaCl, 20 mM EDTA, 0.24 mM S2238, 
and 0.5 mg  of HSA/ml at 37 'C. The amount of amidolytic thrombin 
activity formed was determined in the same way as described for 
factor Xa. 
Kinetic Analysis of the Inhibition of Prothrombin Activation and 
Formed Thrombin Activity-We  modeled the prothrombin activation 
in the presence of A T  111 and heparin by assuming that  the observed 
generation of thrombin activity is the result of its virtual rate of 
formation ( V+l) and  its  rate of inactivation ( Vw1). 
V,, = d[thrombinJ/dt = V+, - V-1 (1) 
Under pseudo-first order conditions the  rate of inactivation of throm- 
bin activity is described by: 
V-, = kl  [thrombin]  (2) 
where kl is the observed pseudo-first order rate  constant of inhibition 
of thrombin activity. Under our conditions the  rate of prothrombin 
activation is directly proportional to  the amount of prothrombinase 
present (ie. factor Xa  concentration): 
V+, = kJXa1 (3) 
where kp is the turnover number, i.e. the number of moles of prothrom- 
bin converted per min/mol of factor Xa under optimum conditions. 
Under pseudo-first order conditions of inactivation of factor Xa, the 
time-dependent factor Xa  concentration  ([Xa],) can be  modeled by: 
P a l ,  = IXaloexp(-krt) (4) 
where [Xa], is the initial factor Xa  concentration, k2 is an  apparent 
pseudo-first order rate  constant of inactivation of factor Xa, and t is 
the reaction time. Assumption of simple pseudo-first order kinetics 
was sufficient to describe the inactivation of factor Xa during the 
bovine prothrombinase reaction by AT 111 or AT I11 and heparin (8).  
Substituting  Equations 2, 3, and 4 into Equation 1 yields: 
Vobe = d[thrombin]/dt = V,exp(-kzt) - kl[thrombin] (5) 
where Vi is the initial rate of prothrombin activation (Vi = kp [Xa],). 
Integration of Equation 5 leads to the following 
[thrombin], = V,(exp(-kzt) - exp(-k,t))/(k, - k2)  (6) 
Equation 6 describes the observed thrombin activity ([thrombin],) in 
terms of initial rate of prothrombin activation ( V,), pseudo-first order 
rate  constants of inhibition of thrombin activity ( k , ) ,  and factor Xa 
(kz )  and reaction time ( t ) .  A close  look at  the equation reveals that 
the rate constants of inhibition of thrombin and factor Xa are 
interchangeable. Thus we optimized our experimental setup by adding 
ST1  after 5 min of prothrombin activation. After the addition of ST1 
at  time t' (V+, = 0) and integration of Equation 5: 
[ th r~mbin]~  = [thrombin],.exp(-kl(t - t ')) (7) 
According to Equation  7 the rate  constant of inhibition of thrombin 
activity can be unequivocally determined and hence also the rate 
constant of inhibition of factor Xa. Equations  6 and 7 were combined 
in a computer program, which made a  non-linear least squares fit of 
the equations to our experimental thrombin activity data using a 
modified Gauss-Newton algorithm (17) and estimated the parameters 
Vi, k,, and kz and  the corresponding 95% confidence intervals, i.e. 
approximately 2 X S.E. of the estimates. 
 at UKB - Universiteit M
aastricht on August 3, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
10004 Inhibition of Prothrombinase  Activity 
24 
4- I 
16 - 
a -  
0 5 10 15 20 
TIME (rnin) 
FIG. 1. Time courses of thrombin activity. Prothrombin was 
activated by factor Xa, factor Va, phospholipid vesicles composed of 
20  mol % phosphatidylserine and 80 mol % phosphatidylcholine, and 
CaC12 as described  under “Experimental Procedures,” in the presence 
of AT 111 and 2.6 (0) or 10.5 nM (A) ISH. ST1  was  added at 5 min. 
The inset shows the semilogarithmic plots of the thrombin  decay  data 
obtained after the addition of STI. Equations 6 and 7 were fitted to 
the data  and the resulting curves  are indicated by the solid lines. 
RESULTS 
T h e  Activation of Prothrombin  in  the  Presence of AT 111 
and Heparin-Prothrombin was activated  in the presence of 
AT I11 and heparin  as described under  “Experimental  Proce- 
dures.’’  Fig. 1 shows typical examples of thrombin generation 
curves prior to  and after the addition of STI.  The  amounts of 
ISH used were 2.6 and 10.5 nM. Equations  6 and 7  (“Experi- 
mental  Procedures”) were fitted to  the experimental data,  and 
the results are depicted as  the solid lines. The inset  in Fig. 1 
shows a semilogarithmic replot of the decay data obtained 
after  the addition of STI.  This decay is monophasic, indicating 
that a single amidolytic active product is generated whose 
reaction with AT I11 should be taken  into account, uiz. mei- 
zothrombin (des  fragment l).’ Clearly, the equations can be 
fitted  to our experimental data very well. The residuals of the 
curves fitted to  the experimental data varied randomly around 
0 and were smaller than 2%. 
The estimated  parameters and  their 95% confidence inter- 
vals were: Vi = 6.2 f 0.2 nM/min, kl = 0.11 + 0.01 min”, and 
kz = 0.14 f 0.02 min” in the presence of  2.6 nM ISH  and Vi 
= 4.0 f 0.2 nM/min, kl = 0.13 f 0.01 rnin”, and k2 = 0.37 f 
0.02 min” in the presence of 10.5 nM ISH.  The initial rate of 
prothrombin  activation,  determined  in the absence of AT I11 
and heparin was Vi = 6.7 nM/min. Hence, it appears that  the 
initial rate of prothrombin  activation is reduced in the pres- 
ence of AT 111 and heparin, In addition, according to the 
pseudo-first order rate constants, the effect of AT I11 and 
heparin on the thrombin generation curves is found in  the 
inactivation of factor Xa ( k z )  rather  than in the inactivation 
of thrombin (kl) .  The effect of heparin and AT I11 on the 
initial rate of prothrombin activation, as well as on the 
pseudo-first order rate  constants of inhibition of thrombin 
activity and factor Xa, will  be further explored in  the following 
sections. 
The  Effect of Heparin  Fragments of Different  Molecular  Size 
on  the  Rate  Constants  of  Inhibition f Prothrombinase  during 
Prothrombin  Activation-Pseudo-first order rate  constants of 
Previous work  from  our laboratory (15) has shown that under the 
conditions of prothrombin activation used in this study, the major 
amidolytic active product is meizothrombin (des-fragment 1) which 
is, throughout this paper,  referred to as thrombin activity. 
factor Xa  inhibition  during  prothrombin  activation were ob- 
tained  as  a function of heparin  concentration for the different 
heparin  preparations,  as  outlined above. The  rate  constants 
were linearly dependent on the heparin  concentrations stud- 
ied. As an example, Fig. 2 shows the pseudo-first order rate 
constants of inhibition of prothrombinase and  the matching 
95% confidence intervals  obtained  in the presence of standard 
heparin. 
The slopes of such plots, calculated by linear regression 
analysis, were determined and are shown in Fig. 3 as function 
of the heparin molecular weight, together with their 95% 
confidence intervals. The results indicate that up to M ,  of 
approximately 6000 no clear relationship is seen between the 
acceleration of inhibition of prothrombinase and  the molec- 
ular size of the heparin fragments. The observed differences 
between the  rate  constants approximate the 95% confidence 
intervals; hence the increasing tendency cannot be regarded 
as significant. However, at molecular weights higher than 
about 6000, a significant increase is noted,  resulting  in  a 10- 
fold increase in  catalytic efficiency over the  entire molecular 
weight range (Table I). 
Comparison between the Rate Constants of Inhibition of 
7 0.4 - 
C .- 
v 
E 
+ 0.3 
2 
2 
m 
0 
0 
w 
0.2 
5 0.1 
0.0 
0 3 6 9 12 
ISH (nu) 
FIG. 2. Rate constants of inactivation of factor Xa during 
prothrombin activation as a function of the concentration of 
standard heparin. The pseudo-first order rate constants and the 
95% confidence intervals were determined as described under “Ex- 
perimental Procedures.” The solid line is obtained by  linear regression 
analysis of the data. 
5 0  L 
i 
/ 
/ 
HEPARIN MOLECULAR WEIGHT 10-3 
FIG. 3. Rate constants of inactivation of prothrombinase 
during prothrombin activation (0) and  of factor Xa (A) as a 
function of the heparin molecular weight. The rate constants 
per  molar  heparin concentration were determined as described  in the 
text. Shown are the values of the rate constants with their 95% 
confidence intervals. 
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Inhibition of Prothrombinase  Activity 10005 
Factor Xu and Prothrombinase-The heparin-dependent 
pseudo-first order rate  constants of inhibition of factor Xa 
were determined as described under “Experimental Proce- 
dures.” We reasoned that a comparison between the heparin- 
dependent inhibition of factor Xa and prothrombinase should 
be made under comparable conditions. Therefore the inhibi- 
tion of factor  Xa was determined in the presence of phospho- 
lipid, Ca2+,  and  prothrombin. For each heparin fragment the 
rate  constants were linearly dependent on the heparin con- 
centration. The slopes of plots of the pseudo-first order rate 
constants  as  a function of the heparin concentrations were 
determined by linear regression analysis. The  data and  their 
95% confidence intervals  are also shown in Fig. 3  and listed 
in Table I. The  data show that  the  rate constants of inhibition 
of factor Xa  are related to  the heparin molecular weight  too. 
Below a molecular weight of about 6,300 a small, but signifi- 
cant increase of the acceleration of the inactivation of factor 
Xa is observed. Between a molecular weight of 6,300 and 
15,000 the catalytic efficiency increases 4-fold. 
When each of the nonenzymatic components were sepa- 
rately examined for an effect on the inhibition of factor Xa, 
we found, in keeping with earlier work on bovine factor  Xa, 
that phospholipids do not  alter  the kinetics of inhibition (7). 
In  contrast to  the inhibition of bovine factor Xa by bovine 
AT 111, Ca2+ ions stimulate the reaction of the human reac- 
tants in the presence of heparin (fractions). A slight stimu- 
lation  (12-fold) was observed with heparin fragments of M, 
< 4500. This  stimulation increased with increasing molecular 
size of the heparin fragment; i.e. the catalytic efficiency of 
heparin  fraction D increased 2.5-fold in the presence of 5 mM 
Ca2+. However, the Ca2+-enhanced accelerating ability was 
diminished when prothrombin was also present in the reaction 
mixture. We could demonstrate that prothrombin dose-de- 
pendently neutralizes the activity of heparins with M, > 6300 
(data  not shown). 
From the  data listed in Table I it is seen that over the entire 
molecular weight range the catalytic specific activities of 
heparin fragments for the inhibition of factor Xa  are  about  5 
times higher compared to their specific activities for the 
inhibition of prothrombinase. The fluctuation of the ratios of 
the specific activities is random, and lies within the experi- 
mental errors. 
Heparin-stimulated Inhibition of Initial Rate of Prothrombin 
Actiuation-We initially assumed that  it would  be sufficient 
to apply a 2-parameter fit, revealing the rate constants of 
inhibition of thrombin ( k l )  and factor Xa ( k 2 ) ,  to model our 
experimental thrombin generation data, and to regard the 
initial rate of prothrombin activation as a non-adjustable 
parameter. However, when Vi was determined in the absence 
of A T  I11 and  heparin and  its value  was  used to compute k,  
TABLE I 
Rate  constants of the  heparin-dependent  inhibition offactor X Q  
and  prothrombinase  by AT III  
Heparin  typ M, 
Rate constant” 
Factor Xa Prothrombinase 
X 1 0 - 7 ~ 1  min“ 
Pentasaccharide 
Octasaccharide 
1,714 1.85 f 0.05 0.23 f 0.07 
2,400 2.1 t 0.1 0.37 f 0.08 
CY216 
10-14 Saccharide 3,600 2.6 f 0.2  0.39 & 0.11 
4,500 3.0 f 0.1 0.68 f 0.22 
ISH 
18-24 Saccharide 6,300 3.3 f 0.1 0.62 f 0.17 
15,000 13.0 f 0.4 3.03 f 0.20 
Heparin  fraction D 20,300 11.1 f 0.3 2.49 f 0.70 
The observed pseudo-first order rate constant divided by the 
molar heparin  concentration as determined by stoichiometric titra- 
tion of AT 111. 
and kZ,  large deviations between the calculated thrombin 
generation data  and  the ones determined experimentally were 
observed in experiments where heparin molecules of a size 
greater than hexadecasaccharide were used. Hence, we did 
not use an independently determined value of V,, but com- 
puted its value  too.  Fig. 4 shows the initial  rates of prothrom- 
bin activation as revealed by the fit procedure, from thrombin 
generation curves obtained in the presence of AT I11 and 
heparin fraction D, the 4th International  Standard for Hepa- 
rin, or the heparin 18-24 saccharide fragment. 
From these  data  it is seen that each of the  three heparins 
causes a  concentration-dependent decrease of the initial  rate 
of prothrombin activation. Inhibition up to nearly 50% of the 
initial value can be obtained. The other heparin preparations, 
pentasaccharide, octasaccharide, 10-14 saccharide, and 
CY216, had no significant inhibitory effect on the initial  rate 
of prothrombin activation in the range of heparin concentra- 
tions we studied. 
We hypothesized that  the observed anomaly between the 
rate,  as determined in  the absence of AT I11 and heparin, and 
the initial  rate, revealed by the fitting of Equation 6 to our 
experimental thrombin generation data in the presence of AT 
I11 and heparins larger than hexadecasaccharide, may be 
accounted for by the instantaneous formation of the dissoci- 
able ternary complex between AT 111, heparin, and factor Xa. 
The formation of this complex results in a  (partial) loss of 
factor Xa activity towards its substrate prothrombin. To rule 
out the possibility that  the observed decrease in the initial 
rate of prothrombin activation is an AT 111-independent effect 
of heparin, we determined the rate of prothrombin activation 
in the absence of AT 111, but in the presence of heparin. 
Thrombin generation was monitored and proceeded linearly 
for at least 5 min. We found that  the rate of prothrombin 
activation was not affected by any of the heparin fractions 
used. Thus, the observed inhibition of the initial rate of 
prothrombin activation is dependent on the presence of both 
AT I11 and heparin. 
In addition, the data shown in Fig. 4 suggest a linear 
decrease of the initial  rate of prothrombin  activation. From 
these plots we calculated a reduction of the initial rate of 
prothrombin activation of 0.38 nM thrombin/min/nM heparin 
fraction D, 0.26 nM thrombin/min/nM ISH, and 0.064 nM 
thrombin/min/nM 18-24 saccharide. Thus, the heparin-in- 
J 
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FIG. 4. Initial rates  of prothrombin activation as a function 
of heparin concentration. The prothrombinase reaction was inhib- 
ited by 0.40 FM AT I11 in the presence of heparin fraction D ( A ) ,  ISH 
( B ) ,  and 18-24 saccharide ( C ) .  The initial  rates  and the 95% confi- 
dence intervals were determined as described under “Experimental 
Procedures.” In the absence of heparin and AT 111 the initial  rate 
was 6.7 nM thrombin/min. 
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duced reduction of the initial rate of thrombin generation 
increases with increasing heparin  chain length. 
Effect of Heparin on the Inhibition of Prothrombinase- 
formed Thrombin Activity-The fitting of Equations 6 and 7 
to  the thrombin  generation data also revealed the  apparent 
pseudo-first order rate constants of inhibition of formed 
thrombin activity. We observed no dependence of the rate 
constants on the  amount of heparin  present  for the different 
heparin preparations. All pseudo-first order rate constants 
varied randomly around  a mean value of 0.137 min-l with a 
maximum value of 0.197 min" and a minimum value of 0.103 
min". This observation is not unexpected, because we previ- 
ously demonstrated that when prothrombin concentrations 
above 1 y~ are used to measure prothrombinase  activity, the 
major reaction product with amidolytic activity is meizo- 
thrombin (des-fragment l), rather  than  &-thrombin,  and  at 
the time we showed that  the AT 111-dependent inhibition of 
meizothrombin (des-fragment 1) is not catalyzed by heparin 
(15). 
DISCUSSION 
The formation of the prothrombinase complex is essential 
for the generation of thrombin at a significant rate (1). AT 
111 and heparin have a potentially important role in the 
regulation of prothrombinase by inhibiting its formation (in- 
activation of free factor Xa)  and/or by inhibiting its activity 
once it is formed. Previous reports (5, 8) have indicated a 
differential activity of free factor  Xa and prothrombinase  in 
their heparin-catalyzed reaction with AT 111. That is, factor 
Va and/or phospholipids appear to protect factor Xa from 
inhibition by AT III/heparin. However, conflicting results 
have been reported regarding the degree of protection (8, 18, 
19) as well as on the effect of the molecular size of heparin 
fragments on the disparity between the rates of inhibition of 
free and complexed factor Xa. This disparity was found to 
increase (8) or decrease (5) with increasing molecular size of 
heparin. 
Our experimental  approach  presented  in this paper is dif- 
ferent from the previously reported ones in that we studied 
the effect of heparin  (fragments) and AT I11 on fully assem- 
bled prothrombinase  during  prothrombin  activation  in  a well 
defined reaction system. We very adequately modeled the 
generation and inactivation of thrombin activity, which al- 
lowed the determination of the  initial  rate of prothrombin 
activation and  the pseudo-first  order rate  constants of inhi- 
bition of generated thrombin  activity and of prothrombinase. 
Progressive Inhibition of Prothrombinase-The pseudo-first 
order rate  constant of inhibition of prothrombinase during 
prothrombin activation in the presence of AT I11 varied 
linearly with the heparin  concentration. Because the AT I11 
concentration was much higher than  the heparin  concentra- 
tions  and reported values for the dissociation constant of the 
heparin-AT I11 interaction (20, 21), it is quite possible that 
essentially all heparin  fragments were saturated with AT 111. 
The catalytic constant derived from the slopes of the lines of 
the  rate  constants plotted versus the molar concentration of 
heparin (mole AT I11 binding site/L) was about 3-6 X lo6 M" 
min" for heparin  fragments with M ,  between 1700 and 6300. 
At  molecular weights higher than 6300 the ability of heparin 
to enhance the inhibition of prothrombinase during pro- 
thrombin  activation  in the presence of A T  I11 increases 4-6- 
fold. Our results indicate that, on a molar basis, heparin 
fragments with low M, (<6000) are less effective than frag- 
ments of higher M ,  in  inhibiting  prothrombinase. 
Instantaneous  Inhibition of Prothrombinase-Our approach 
to examining the inhibitory  action of AT  III/heparin  during 
the prothrombinase reaction resulted in an,  until now, unrec- 
ognized  mode of action of AT III/heparin on prothrombinase- 
catalyzed thrombin generation. Evidence was obtained that 
in addition to  the progressive inhibition of prothrombinase, 
AT  III/heparin causes an immediate, partial neutralization of 
the prothrombinase activity. That is, the initial rate of pro- 
thrombin activation decreases with increasing amounts of 
heparin. Moreover, this direct inhibitory action was much 
more pronounced for heparin  fragments with higher M ,  than 
for low M, heparins. In the absence of A T  I11 none of the 
heparins studied inhibit prothrombin activation. This rules 
out that under these conditions heparin inhibits the pro- 
thrombinase reaction by disrupting the prothrombinase com- 
plex (22). We hypothesize that  the initial, very rapid,  forma- 
tion of the  ternary complex between factor Xa, heparin, and 
A T  I11 directly removes factor Xa from the prothrombinase 
complex and thereby reduces the  amount of prothrombinase 
available. Alternatively, the prothrombinase  in the dissociable 
complex with heparin and AT I11 may have a reduced activity 
towards prothrombin. Unfortunately, an  attempt  to  further 
reduce the initial rate of prothrombin  activation by increasing 
the heparin  concentration failed because the progressive in- 
hibition of prothrombinase became too  fast to give reliable 
thrombin generation data for the fit procedure. 
Disparity between Rates of Znhibition of Factor Xa and 
Prothrombinase-The pseudo-first order rate  constant of in- 
hibition of factor  Xa increases linearly with the concentration 
of the various heparin  fragments. Thus we assumed that all 
heparin was saturated with AT I11 as was the case in the 
experiments with prothrombinase. The dependence of the 
catalytic constant on the molecular size of the heparin frag- 
ment agrees closely with the  data reported for bovine factor 
Xa (4, 5 ) .  That is, the catalytic efficiencies of the heparin 
fragments, based on their AT 111-binding molar concentra- 
tion, decreased with decreasing molecular size. The scarce 
data available on  human factor Xa (5)  indicate that Ca2+ ions 
accelerate the factor Xa-AT I11 reaction 1.2-fold when un- 
fractionated  heparin was present but  not in the case of oligo- 
saccharide fragments. We confirmed that  the Ca2+-induced 
acceleration increased with increasing molecular size of the 
heparin fragments. However, this stimulation  appears to be 
counterbalanced by the heparin  neutralizing  property of pro- 
thrombin. 
Our data clearly indicate  a higher catalytic  activity of each 
heparin  fragment for factor Xa inhibition than for the  inhi- 
bition of prothrombinase. In  contrast with the observation of 
Barrowcliffe et al. (5),  heparin  fragments of high M, are  unable 
to overcome the protective effect of factor Va on the inhibition 
of factor Xa. In fact, the disparity between the catalytic 
constants when compared under identical conditions was 
found to be independent of the molecular size of the heparin 
fragments. 
In summary, the results presented in this paper suggest 
that a  saccharide sequence, additional to  the unique penta- 
saccharide sequence required for A T  I11 binding  (23), stimu- 
lates the inhibition of prothrombinase to  the same degree as 
was observed for factor Xa in the absence of factor Va. In 
addition, such a non-AT I11 binding saccharide structure 
induces: 1) a second mode of action of heparin, i.e. a  direct 
inhibition of the initial rate of thrombin  generation and 2) a 
Ca2+-stimulated  inhibition of factor Xa. 
At  present  it is unclear which properties of the additional 
saccharide sequence are responsible for our observations. IS 
it  the length per se which gives these effects or  is  there  an 
involvement of additional structural features of the heparin 
chain? In this respect, it has been demonstrated that the 
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bimolecular rate  constant of the heparin-catalyzed inactiva- 
tion of factor Xa by AT I11 is dependent on  ionic strength in 
the presence of a high affinity M ,  8000 heparin, whereas an 
ionic strength independence is seen in the presence of a 
pentasaccharide (24). This observation is indicative of an 
electrostatic  interaction between factor Xa  and  the M ,  8000 
heparin.  Thus, an effect of heparin charge density, which is 
well established for heparin-catalyzed thrombin inactivation 
(25,26), may contribute to  the heparin M, effects we observed. 
However, we cannot rule out that after the first  encounter of 
heparin and AT I11 in the pentasaccharide region, secondary 
interactions between heparin and AT 111 occur (27,28), which 
may also contribute to our observations. 
The catalytic constants were calculated on the basis of 
molar concentration of AT 111-binding sites  and all these  sites 
were saturated with AT 111. Therefore it is our conclusion 
that although simultaneous binding of AT 111 and factor Xa 
or prothrombinase to the same heparin molecule is not a 
prerequisite for the acceleration of inhibition, it does increase 
the catalytic efficiency of the heparin molecule. Moreover, 
linkage of protease-AT 111-heparin interactions,  as recently 
demonstrated for the reaction with thrombin (21) may also 
contribute to  the involvement of heparin chain length in the 
heparin-catalyzed inhibition of prothrombinase by A T  111. 
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